MBNL1 and hepatocellular carcinoma: In the study of HCC, exosome-derived lnc-FAM72D-3 [26], which serves as a diagnostic and prognostic biomarker, promotes cytoskeleton remodeling via the MBNL1/FAK axis, thereby enhancing HCC cell resistance to lenvatinib and elucidating the molecular mechanisms underlying HCC drug resistance [28].